Selegiline reduces N-methyl-D-aspartic acid induced perturbation of neurotransmission but it leaves NMDA receptor dependent long-term potentiation intact in the hippocampus

Journal of Neural Transmission

Volumn 110, Issue 11, 2003, Pages 1225-1240

  Niittykoski, M ^a   Haapalinna, A ^b   Sirvio J ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b ORION CORPORATION   (Finland)

Author keywords

Hippocampus; L deprenyl; MAO inhibitors; NMDA receptors; Pargyline; Synaptic transmission

Indexed keywords

MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PARGYLINE; SELEGILINE;

ADOLESCENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; EXCITATORY POSTSYNAPTIC POTENTIAL; FACILITATION; HIPPOCAMPUS; LONG TERM POTENTIATION; MALE; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; SYNAPTIC TRANSMISSION;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EXCITATORY POSTSYNAPTIC POTENTIALS; GLUTAMIC ACID; HIPPOCAMPUS; LONG-TERM POTENTIATION; MALE; MONOAMINE OXIDASE INHIBITORS; N-METHYLASPARTATE; NEURONS; PARGYLINE; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; SELEGILINE; SYNAPTIC TRANSMISSION;

EID: 0345059237     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-003-0035-5     Document Type: Article

References (33)

1. Alafuzoff I, Helisalmi S, Heinonen EH, Reinikainen K, Hallikainen M, Soininen H, Koivisto K (2000) Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer's disease. Eur J Clin Pharmacol 55: 815-819
2. Arai A, Lynch G (1992) Factors regulating the magnitude of long-term potentiation induced by theta pattern stimulation. Brain Res 598: 173-184
3. Barbelivien A, Nyman L, Haapalinna A, Sirviö J (2001) Inhibition of MAO-A activity enhances behavioural activity of rats assessed using water maze and open arena tasks. Pharmacol Toxicol 88: 304-312
4. Choi DW (1988) Glutamate neurotoxicity and diseases of the nervous system. Neuron 1: 623-634
5. Collins DR, Davies SN (1994) Potentiation of synaptic transmission in the rat hippocampal slice by exogenous L-glutamate and selective L-glutamate receptor subtype agonists. Neuropharmacology 33: 1055-1063
6. Farber NB, Wozniak DF, Price MT, Labruyere J, Huss J, St Peter H, Olney JW (1995) Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia? Biol Psychiatry 38: 788-796
7. Fowler CJ, Mantle TJ, Tipton KF (1982) The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, 1-deprenyl and pargyline. Biochem Pharmacol 31: 3555-3561
8. Gelowitz DL, Paterson IA (1999) Neuronal sparing and behavioral effects of the antiapoptic drug, (-)deprenyl, following kainic acid administration. Pharmacol Biochem Behav 62: 255-262
9. Heinonen EH, Lammintausta R (1991) A review of the pharmacology of selegiline. Acta Neurol Scand [Suppl] 136: 44-59
10. Hsu K-S, Huang C-C, Su M-T, Tsai J-J (1996) L-Deprenyl (selegiline) decreases excitatory synaptic transmission in the rat hippocampus via a dopaminergic mechanism. J Pharmacol Exp Ther 279: 740-747
11. Knoll J (1998) (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain. Pharmacol Toxicol 82: 57-66
12. Lahtinen H, Koistinaho J, Kauppinen R, Haapalinna A, Keinänen R, Sivenius J (1997) Selegiline treatment after transient global ischemia in gerbils enhances the survival of CA1 pyramidal cells in the hippocampus. Brain Res 757: 260-267
13. Larson J, Wong D, Lynch G (1986) Patterned stimulation at the theta frequency is optimal for the induction of hippocampal potentiation. Brain Res 368: 347-350
14. +)-induced apoptosis independent of MAO-B inhibition. Neurosci Lett 224: 197-200
15. Maruyama W, Takahashi T, Naoi M (1998) (-)-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide. J Neurochem 70: 2510-2515
16. McEntee WJ, Crook TH (1993) Glutamate: its role in learning, memory, and the aging brain. Psychopharmacology 111: 391-401
17. Meldrum B, Garthwaite J (1990) Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 11: 379-387
18. Myllylä VV, Sotaniemi KA, Vuorinen JA, Heinonen E (1992) Selegiline as initial treatment in de novo parkinsonian patients. Neurology 42: 339-343
19. Mytilineou C, Radcliffe P, Leonardi EK, Werner P, Olanow CW (1997) L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro. J Neurochem 68: 33-39
20. Niittykoski M, Haapalinna A, Sirviö J (2000) Diminution of N-methyl-D-aspartate-induced perturbation of neurotransmission by dexmedetomidine in the CA1 field of rat hippocampus in vitro. Neurosci Lett 281: 95-98
21. Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, Bushenbark K, Lilienfeld D, Esterlitz J (1995) The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 38: 7712-7777
22. Ozawa S, Kamiya H, Tsuzuki K (1998) Glutamate receptors in the mammalian central nervous system. Prog Neurobiol 54: 581-618
23. Paterson IA, Barber AJ, Gelowitz DL, Voll C (1997) (-)Deprenyl reduces delayed neuronal death of hippocampal pyramidal cells. Neurosci Biobehav Rev 21: 181-186
24. Pereira CMF, Oliveira CR (1997) Glutamate toxicity on PC12 cell line involves glutathione (GSH) depletion and oxidative stress. Free Radic Biol Med 23: 637-647
25. Puurunen K, Jolkkonen J, Sirviö J, Haapalinna A, Sivenius J (2001) Selegiline combined with enriched-environment housing attenuates spatial learning deficits following focal cerebral ischemia in rats. Exp Neurol 167: 348-355
26. Ravikumar R, Lakshmana MK, Shankaranarayana Rao BS, Meti BL, Bindu PN, Raju TR (1998) (-)-Deprenyl attenuates spinal motor neuron degeneration and associated locomotor deficits in rats subjected to spinal cord ischemia. Exp Neurol 149: 123-129
27. Schulz PE, Cook EP, Johnston D (1994) Changes in paired-pulse facilitation suggest presynaptic involvement in long-term potentiation. J Neurosci 14: 5325-5337
28. Shimazu S, Katsuki H, Akaike A (1999) Deprenyl rescues dopaminergic neurons in organotypic slice cultures of neonatal rat mesencephalon from N-methyl-D-aspartate toxicity. Eur J Pharmacol 377: 29-34
29. Sivenius J, Sarasoja T, Aaltonen H, Heinonen E, Kilkku O, Reinikainen K (2001) Selegiline treatment facilitates recovery after stroke. Neurorehabil Neural Repair 15: 183-190
30. Tatton WG, Greenwood CE (1991) Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 30: 666-672
31. Tatton WG, Ju WYL, Holland DP, Tai C, Kwan M (1994) (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 63: 1572-1575
32. Tetrud JW, Langston JW (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 245: 519-522
33. Yavich L, Sirviö J, Heinonen E, Riekkinen P (1993) The interaction of L-deprenyl and scopolamine on spatial learning/memory in rats. J Neural Transm [PD Sect] 6: 189-197